1. Mesfin FB, Karsonovich T, Al-Dhahir MA. Gliomas. StatPearls [Internet]: StatPearls Publishing; 2024. [
Article]
2. Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2(9): 494-503. [
DOI]
3. Larjavaara S, Mäntylä R, Salminen T, et al. Incidence of gliomas by anatomic location. Neuro Oncol 2007; 9(3): 319-325. [
DOI]
4. Pellerino A, Caccese M, Padovan M, et al. Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging 2022; 10(5): 467-475. [
DOI]
5. Zakariaee SS, Hashemi H, Salmanipour H. Comparison of singular value decomposition and Fourier deconvolution methods for cerebral blood flow quantification in dynamic contrastenhanced magnetic resonance imaging. J Res Med Sci 2022; 9(4): 57-68. [
Article]
6. Zakariaee SS, Oghabian MA, Firouznia K, et al. Assessment of the agreement between cerebral hemodynamic indices quantified using dynamic susceptibility contrast and dynamic contrastenhanced perfusion magnetic resonance imagings. J Clin Imaging Sci 2018; 8: 1-9. [
DOI]
7. Muragaki Y, Chernov M, Maruyama T, et al. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Surg 2008; 51(5): 275-279. [
DOI]
8. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001; 3(3): 193-200. [
DOI]
9. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24(10): 1989-1998. [
Article]
10. Abdi AI. Glioma grading using an optimized T1-weighted dynamic contrastenhanced magnetic resonance imaging paradigm. Egypt J Radiol Nucl Med 2024; 55(1): 1-12. [
DOI]
11. Eilaghi A, Yeung T, d'Esterre C, et al. Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images: Supplementary Issue: Biomarkers and their Essential Role in the Development of Personalised Therapies. Biomark Cancer 2016; 8(Suppl 2): 47-59. [
DOI]
12. Aydin S, Fatihoğlu E, Koşar PN, et al. Perfusion and permeability MRI in glioma grading. Egypt J Radiol Nucl Med 2020; 51(1): 1-8. [
DOI]
13. Ma H, Zeng S, Huang Y, et al. Predicting glioma histomolecular diagnosis and prognosis: preoperative dynamic contrast-enhanced magnetic resonance imaging insights. Quant Imaging Med Surg 2025; 15(10): 9855-9870. [
DOI]
14. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013; 310(20): 2191-2194. [
DOI]
15. Walke V, Joshi D, Sharma T, et al. The spectrum of microvascular patterns in adult diffuse glioma and their correlation with tumor grade. J Pathol Transl Med 2024; 58(3): 127-133. [
DOI]
16. Muthukrishnan SD, Qi H, Wang D, et al. Low-and high-grade glioma-associated vascular cells differentially regulate tumor growth. Mol Cancer Res 2024; 22(7): 656-667. [
DOI]
17. Zhao J, Yang ZY, Luo BN, et al. Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors. PLoS One 2015; 10(9): e0138573. [
DOI]
18. Mills SJ, Soh C, O’connor JP, Rose CJ, Buonaccorsi GA, Cheung S, Zhao S, Parker GJ, Jackson A. Tumour enhancing fraction (EnF) in glioma: relation-ship to tumour grade. European Radiology 2009; 19(6): 1489-1498. [
DOI]